ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why Integra LifeSciences (IART) Shares Are Sliding Today

IART Cover Image

What Happened?

Shares of medical device company Integra LifeSciences (NASDAQ: IART) fell 23% in the morning session after it reported third-quarter sales that missed expectations and provided a weak financial outlook. The company's revenue of $402.1 million fell short of Wall Street's projections. While its adjusted earnings per share of $0.54 surpassed estimates, this was overshadowed by disappointing forward-looking guidance. Integra's revenue forecast for the fourth quarter came in at $430 million, well below what analysts had anticipated. Adding to investor concerns, the company also lowered its adjusted earnings per share guidance for the full year.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here.

What Is The Market Telling Us

Integra LifeSciences’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. But moves this big are rare even for Integra LifeSciences and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 15 days ago when the stock dropped on the news that Truist raised its price target on the stock to $15 from $13, ahead of the company's third-quarter results. The firm kept a Hold rating on the shares. The analyst mentioned in a research note that they expected “healthy” Q3 revenue and earnings across the medical technology sector but also braced for “stock volatility.” The note also stated that new money felt notably absent from the space and that there could be excessive reactions to anything counter to crowded positioning. This news came as Integra LifeSciences had previously announced it would release its third-quarter financial results on October 30.

Integra LifeSciences is down 49.1% since the beginning of the year, and at $11.71 per share, it is trading 56.1% below its 52-week high of $26.70 from November 2024. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $265.61.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.99
-3.11 (-1.25%)
AAPL  273.29
-1.96 (-0.71%)
AMD  261.45
+23.93 (10.07%)
BAC  54.63
+1.00 (1.87%)
GOOG  287.39
-4.35 (-1.49%)
META  615.25
-11.83 (-1.89%)
MSFT  505.81
-2.88 (-0.57%)
NVDA  192.09
-1.07 (-0.55%)
ORCL  231.18
-4.97 (-2.10%)
TSLA  432.40
-7.22 (-1.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.